Straumann is granted a controlling interest in Medentika

Straumann has signed an agreement with the other shareholders of Medentika to obtain a controlling interest in Medentika. At the same time Straumann is acquiring Medentika's share of their jointly-held distribution business in Germany, Medentika's biggest market.

The two companies became partners three years ago, when Straumann purchased a 51% non-controlling stake in Medentika. The original agreement foresaw Straumann gaining a controlling interest in November 2017 but the two companies have agreed to bring this forward in order to deepen their relationship and to add organizational clarity to their common activities.

With effect of 1 January 2017, Straumann will therefore fully consolidate Medentika's financial statements and balance sheet. The ownership structure of Medentika – and Straumann's stake – remain unchanged and the founding shareholders will continue to have an active role in the company.

The partnership between the two companies has been highly successful: through its Instradent platform, Straumann has assisted Medentika's international expansion and has made a significant contribution to the company's development and sustainable growth. For its part, Medentika has contributed significantly to Straumann's strategic goals of providing comprehensive solutions to dental labs and becoming a global leader in the 'value' segment of the tooth-replacement market.

About Medentika

Founded in 2005 and based in Hügelsheim, Germany, Medentika is a fast-growing provider of attractively-priced implant prosthetics for most leading implant and CADCAM systems. The company also supplies a range of titanium implants and instruments and is certified to EN ISO 13485:2007 and AC:2009.

With a staff of approximately 70, Medentika is highly profitable and generated revenues of approximately CHF 20 million in 2015. Straumann will also recognize a financial liability of approximately CHF 46 million in connection with the accounting treatment of the outstanding minority stake. Apart from this, no other significant impacts are to be expected.

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 3600 people worldwide and its products and services are available in more than 100 countries through its broad network of distribution subsidiaries and partners. To complement its core premium business, Straumann has established the Instradent business platform to address the global non-premium segment with various brands that it either owns or in which it has invested including Anthogyr, equinox, Medentika and Neodent.